Euda highlights Shenzhen Inno approval for Shenzhen R&D program TCR-T project
PUBT · 20h ago
Share
Listen to the news
- EUDA Health highlighted Shenzhen Inno Immune’s clearance under Shenzhen 2025 Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
- Shenzhen Science and Technology Innovation Bureau may provide funding up to USD 434,688 for project running Jan. 1, 2026 to Dec. 31, 2028.
- EUDA holds non-exclusive rights to market selected Shenzhen Inno immunotherapies in Malaysia, with treatments conducted in China.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-019415), on April 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved